Table 3.
Effects of compounds 1–16 on viability of human breast cancer cells (MCF-7 and MDA-MB-231) and normal breast cells (MCF-10A).
| Compound | IC50 (μM) |
||
|---|---|---|---|
| MCF-7 | MDA-MB-231 | MCF-10A | |
| 1 | 1.6±0.1 | 2.8±0.2 | 27.9±2.3 |
| 2 | 3.4±0.2 | 10.7±0.7 | >50 |
| 3 | 7.8±0.5 | 16.5±1.3 | >50 |
| 4 | 3.7±0.2 | 5.7±0.5 | 26.4±2.5 |
| 5 | 13.7±0.6 | 21.1±1.7 | >50 |
| 6 | >50 | >50 | >50 |
| 7 | >50 | >50 | >50 |
| 8 | 6.7±0.5 | 12.9±0.9 | >50 |
| 9 | >50 | >50 | >50 |
| 10 | >50 | >50 | >50 |
| 11 | 15.5±0.9 | 25.8±2.1 | >50 |
| 12 | 12.6±1.1 | 28.6±1.9 | >50 |
| 13 | 6.2±0.3 | 11.4±0.5 | >50 |
| 14 | 2.1±0.3 | 2.3±0.1 | 26.0±1.2 |
| 15 | >50 | >50 | >50 |
| 16 | 6.9±0.4 | 13.8±1.2 | 45.7±2.5 |
| Doxorubicina (μM) | 0.7±0.06 | 0.9±0.1 | 2.8±0.2 |
| Paclitaxelb (nM) | 75.2±5.8 | 87.0±9.6 | 427.0±55.4 |
a,b
Positive controls: Doxorubicin (98.0–102.0%, HPLC, Sigma); Paclitaxel (>97.0%, Sigma).